domperidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antipsychotics, risperidone derivatives	945	57808-66-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: domperidone betadex domperidone betacyclodextrin domperidone motilium peridon domperidone maleate	A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. Molecular weight: 425.92 Formula: C22H24ClN5O2 CLOGP: 3.87 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 67.92 ALOGS: -3.66 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

domperidone betadex
domperidone betacyclodextrin
domperidone
motilium
peridon
domperidone maleate

A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

Molecular weight: 425.92
Formula: C22H24ClN5O2
CLOGP: 3.87
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 67.92
ALOGS: -3.66
ROTB: 5

Drug dosage:

Dose	Unit	Route
30	mg	O
30	mg	P
0.12	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	3.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1982	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature labour	154.57	11.89	94	31750	11382	50561898
Derealisation	129.09	11.89	41	31803	1005	50572275
Gastric pH decreased	124.97	11.89	36	31808	626	50572654
Depersonalisation/derealisation disorder	111.74	11.89	38	31806	1160	50572120
H1N1 influenza	90.29	11.89	35	31809	1562	50571718
Cogwheel rigidity	86.66	11.89	35	31809	1742	50571538
Dissociation	84.53	11.89	37	31807	2254	50571026
Feeling of despair	82.36	11.89	35	31809	1983	50571297
Hypoaesthesia oral	82.28	11.89	62	31782	10666	50562614
Hyperprolactinaemia	76.76	11.89	39	31805	3326	50569954
Drug ineffective	73.20	11.89	268	31576	819065	49754215
Pulmonary malformation	70.85	11.89	18	31826	189	50573091
Completed suicide	66.96	11.89	4	31840	131885	50441395
Sensory loss	66.74	11.89	48	31796	7690	50565590
Drooling	65.13	11.89	35	31809	3349	50569931
Systemic lupus erythematosus	63.83	11.89	7	31837	140615	50432665
Muscle disorder	62.10	11.89	37	31807	4313	50568967
Pituitary tumour benign	60.04	11.89	27	31817	1754	50571526
Feeling of body temperature change	59.38	11.89	36	31808	4331	50568949
Vomiting	58.76	11.89	492	31352	460266	50113014
Menstrual disorder	56.80	11.89	35	31809	4335	50568945
Parosmia	56.32	11.89	35	31809	4401	50568879
Hallucinations, mixed	56.24	11.89	34	31810	4069	50569211
Cestode infection	55.93	11.89	16	31828	271	50573009
Restless legs syndrome	55.74	11.89	59	31785	15838	50557442
Product dose omission issue	54.07	11.89	24	31820	183814	50389466
Nightmare	53.41	11.89	58	31786	16028	50557252
Dyskinesia	53.06	11.89	76	31768	27785	50545495
Therapeutic product ineffective	51.74	11.89	22	31822	1248	50572032
Muscle rigidity	50.51	11.89	45	31799	9784	50563496
Gangrene	49.62	11.89	33	31811	4659	50568621
On and off phenomenon	49.50	11.89	22	31822	1390	50571890
Mydriasis	49.42	11.89	46	31798	10581	50562699
Arterial occlusive disease	48.89	11.89	33	31811	4775	50568505
Mood swings	48.62	11.89	55	31789	15899	50557381
Schizophrenia	48.58	11.89	39	31805	7358	50565922
Stoma site erythema	48.50	11.89	19	31825	872	50572408
Stoma site discharge	48.37	11.89	21	31823	1254	50572026
Contraindicated product administered	47.80	11.89	17	31827	148941	50424339
Psychotic disorder	46.77	11.89	63	31781	21749	50551531
Dystonia	46.76	11.89	47	31797	11879	50561401
Arthropathy	45.82	11.89	21	31823	157885	50415395
Decreased appetite	45.75	11.89	248	31596	200675	50372605
Synovitis	45.48	11.89	11	31833	123854	50449426
Lung cyst	44.47	11.89	12	31832	162	50573118
Hypersensitivity	44.37	11.89	42	31802	215119	50358161
Neutropenic sepsis	43.50	11.89	49	31795	14098	50559182
Therapeutic product effect decreased	42.85	11.89	16	31828	136034	50437246
Electrocardiogram QT prolonged	42.43	11.89	98	31746	51788	50521492
Abdominal discomfort	41.35	11.89	51	31793	231590	50341690
Respiratory tract malformation	41.05	11.89	10	31834	87	50573193
Glossodynia	41.01	11.89	11	31833	115558	50457722
Akathisia	40.95	11.89	37	31807	8192	50565088
Forced vital capacity decreased	40.67	11.89	17	31827	924	50572356
Lung diffusion test decreased	40.39	11.89	15	31829	594	50572686
Premenstrual syndrome	40.32	11.89	15	31829	597	50572683
Neuroleptic malignant syndrome	40.26	11.89	42	31802	11088	50562192
Inguinal hernia	39.58	11.89	20	31824	1686	50571594
Magnesium deficiency	39.45	11.89	14	31830	486	50572794
Paralysis	39.32	11.89	37	31807	8627	50564653
Rash	38.90	11.89	143	31701	437328	50135952
Basal ganglion degeneration	38.28	11.89	13	31831	395	50572885
Pericarditis	38.14	11.89	3	31841	78686	50494594
Maternal exposure during pregnancy	38.13	11.89	27	31817	159751	50413529
Tissue infiltration	38.08	11.89	14	31830	539	50572741
Lip pruritus	37.50	11.89	15	31829	728	50572552
Secondary adrenocortical insufficiency	37.49	11.89	17	31827	1126	50572154
Emotional disorder	34.70	11.89	40	31804	11796	50561484
Hallucination, auditory	34.43	11.89	38	31806	10690	50562590
Wound	34.06	11.89	12	31832	105782	50467498
Mania	33.89	11.89	38	31806	10878	50562402
Lichen sclerosus	33.42	11.89	15	31829	970	50572310
Hepatic enzyme increased	33.06	11.89	23	31821	137357	50435923
Hand deformity	32.89	11.89	11	31833	100188	50473092
Hyperchlorhydria	32.80	11.89	17	31827	1511	50571769
Skin discolouration	32.63	11.89	67	31777	32690	50540590
Serotonin syndrome	32.62	11.89	57	31787	24656	50548624
Total lung capacity decreased	32.50	11.89	16	31828	1275	50572005
Maternal exposure during breast feeding	32.29	11.89	22	31822	3232	50570048
Uterine enlargement	32.28	11.89	15	31829	1051	50572229
Exposure via breast milk	31.98	11.89	17	31827	1591	50571689
Polymenorrhoea	31.69	11.89	15	31829	1096	50572184
Incontinence	31.41	11.89	35	31809	9950	50563330
Tinnitus	30.97	11.89	60	31784	28072	50545208
Menstruation delayed	30.94	11.89	16	31828	1415	50571865
Blood sodium decreased	30.85	11.89	51	31793	21096	50552184
Treatment failure	29.38	11.89	26	31818	137611	50435669
Biliary sepsis	29.02	11.89	13	31831	837	50572443
Body temperature fluctuation	28.73	11.89	17	31827	1956	50571324
Paranoia	28.72	11.89	34	31810	10314	50562966
Anti-cyclic citrullinated peptide antibody positive	28.52	11.89	5	31839	70582	50502698
Cyanosis	28.29	11.89	41	31803	15143	50558137
Subileus	28.20	11.89	19	31825	2740	50570540
Anaesthesia	28.10	11.89	10	31834	350	50572930
Bronchopulmonary aspergillosis allergic	27.74	11.89	14	31830	1177	50572103
Unresponsive to stimuli	27.46	11.89	60	31784	30549	50542731
Chronic sinusitis	27.42	11.89	26	31818	6119	50567161
Abdominal tenderness	27.28	11.89	28	31816	7252	50566028
Thyroid stimulating immunoglobulin increased	27.17	11.89	7	31837	78	50573202
Blepharospasm	27.06	11.89	19	31825	2929	50570351
Freezing phenomenon	26.81	11.89	13	31831	1002	50572278
Mental disorder	26.81	11.89	49	31795	21942	50551338
Joint swelling	26.79	11.89	73	31771	245213	50328067
Rhinalgia	26.68	11.89	13	31831	1013	50572267
Feeling jittery	26.66	11.89	34	31810	11126	50562154
Nail dystrophy	26.40	11.89	12	31832	799	50572481
Stoma site hypergranulation	26.30	11.89	9	31835	280	50573000
Folate deficiency	26.28	11.89	16	31828	1939	50571341
Hypokalaemia	25.96	11.89	117	31727	87875	50485405
Gastritis fungal	25.77	11.89	7	31837	97	50573183
Adrenal suppression	25.57	11.89	12	31832	860	50572420
Discomfort	24.96	11.89	19	31825	108361	50464919
Cardiac failure congestive	24.81	11.89	11	31833	84371	50488909
Restlessness	24.49	11.89	51	31793	25122	50548158
Neuropathy peripheral	24.44	11.89	123	31721	96634	50476646
Adverse drug reaction	24.42	11.89	3	31841	55219	50518061
Tremor	24.22	11.89	139	31705	114764	50458516
Limbic encephalitis	24.14	11.89	8	31836	225	50573055
Vascular encephalopathy	23.67	11.89	9	31835	381	50572899
Lung opacity	23.62	11.89	15	31829	1958	50571322
Torsade de pointes	23.58	11.89	33	31811	11802	50561478
Stoma site pain	23.39	11.89	11	31833	792	50572488
Constipation	23.37	11.89	198	31646	185510	50387770
Stoma site inflammation	23.29	11.89	9	31835	398	50572882
Infection	23.28	11.89	46	31798	172908	50400372
Glomerulonephritis chronic	23.10	11.89	7	31837	146	50573134
Pallor	22.57	11.89	47	31797	23152	50550128
Pulmonary function test decreased	22.54	11.89	18	31826	3370	50569910
Heart rate increased	22.25	11.89	102	31742	77148	50496132
Suicidal ideation	22.20	11.89	81	31763	55304	50517976
Urinary retention	21.99	11.89	50	31794	26140	50547140
Febrile neutropenia	21.81	11.89	120	31724	97547	50475733
Delirium	21.77	11.89	63	31781	38129	50535151
Psychogenic seizure	21.38	11.89	13	31831	1572	50571708
Overdose	21.08	11.89	19	31825	99708	50473572
Hypochromic anaemia	20.57	11.89	13	31831	1683	50571597
Adrenal insufficiency	20.31	11.89	34	31810	14209	50559071
Swelling	20.30	11.89	62	31782	200810	50372470
Irritable bowel syndrome	20.02	11.89	4	31840	51437	50521843
Terminal ileitis	19.76	11.89	9	31835	602	50572678
Speech disorder	19.65	11.89	58	31786	35490	50537790
Stoma site infection	19.62	11.89	9	31835	612	50572668
Neurological decompensation	19.39	11.89	14	31830	2256	50571024
Oral cavity fistula	19.32	11.89	9	31835	634	50572646
Pyrexia	19.26	11.89	341	31503	379862	50193418
Rheumatoid factor positive	19.15	11.89	4	31840	49855	50523425
Sputum discoloured	19.13	11.89	32	31812	13363	50559917
Gastric disorder	19.07	11.89	51	31793	29497	50543783
Galactorrhoea	19.04	11.89	17	31827	3706	50569574
Stoma complication	18.98	11.89	7	31837	272	50573008
Monoplegia	18.97	11.89	15	31829	2768	50570512
Axillary pain	18.86	11.89	12	31832	1572	50571708
Carcinoid tumour	18.30	11.89	7	31837	301	50572979
Nail bed tenderness	17.85	11.89	7	31837	322	50572958
Disorientation	17.84	11.89	56	31788	35428	50537852
Impaired healing	17.70	11.89	11	31833	69775	50503505
Chest discomfort	17.51	11.89	109	31735	92613	50480667
Injection site erythema	17.42	11.89	13	31831	74923	50498357
Feeling abnormal	17.21	11.89	33	31811	125459	50447821
Hypomagnesaemia	17.05	11.89	42	31802	23114	50550166
Acute hepatic failure	16.72	11.89	33	31811	15644	50557636
Lung disorder	16.68	11.89	64	31780	44735	50528545
Infusion site vesicles	16.56	11.89	7	31837	391	50572889
Vision blurred	16.47	11.89	95	31749	78552	50494728
Off label use	16.32	11.89	402	31442	474024	50099256
Anti-thyroid antibody positive	16.27	11.89	7	31837	409	50572871
Dementia	16.26	11.89	33	31811	15964	50557316
Aphasia	16.24	11.89	47	31797	28447	50544833
Abdominal pain	16.18	11.89	223	31621	236005	50337275
Weight decreased	16.04	11.89	211	31633	221034	50352246
Drug withdrawal syndrome	15.89	11.89	43	31801	25038	50548242
Stoma site extravasation	15.87	11.89	6	31838	250	50573030
Epilepsy	15.75	11.89	39	31805	21528	50551752
Psoriatic arthropathy	15.71	11.89	5	31839	47027	50526253
Angina pectoris	15.70	11.89	44	31800	26144	50547136
Renal failure	15.55	11.89	27	31817	106606	50466674
Bezoar	15.52	11.89	10	31834	1338	50571942
Gastrointestinal sounds abnormal	15.50	11.89	15	31829	3619	50569661
Autonomic neuropathy	15.47	11.89	9	31835	1004	50572276
Dermatitis exfoliative generalised	15.44	11.89	14	31830	3112	50570168
Therapeutic product effect incomplete	15.42	11.89	21	31823	91494	50481786
Folliculitis	15.37	11.89	3	31841	39222	50534058
Duodenal stenosis	15.09	11.89	7	31837	489	50572791
Dysaesthesia pharynx	15.01	11.89	5	31839	143	50573137
Oral candidiasis	14.99	11.89	33	31811	16882	50556398
Injury	14.98	11.89	6	31838	48919	50524361
Taste disorder	14.82	11.89	22	31822	8302	50564978
Cataract	14.78	11.89	64	31780	47236	50526044
Sprue-like enteropathy	14.73	11.89	7	31837	516	50572764
Mucosal inflammation	14.66	11.89	57	31787	40085	50533195
Repetitive strain injury	14.63	11.89	5	31839	155	50573125
Thyroxine free increased	14.62	11.89	8	31836	793	50572487
Microvillous inclusion disease	14.50	11.89	3	31841	11	50573269
Paraesthesia	14.48	11.89	127	31717	120116	50453164
Cardio-respiratory arrest	14.37	11.89	8	31836	53884	50519396
Hospitalisation	14.29	11.89	13	31831	67924	50505356
Needle issue	14.07	11.89	20	31824	7255	50566025
Ejection fraction decreased	14.07	11.89	34	31810	18486	50554794
Impaired gastric emptying	14.05	11.89	22	31822	8696	50564584
Vulvovaginal pruritus	13.97	11.89	12	31832	2484	50570796
Functional residual capacity decreased	13.97	11.89	4	31840	68	50573212
Sleep disorder	13.88	11.89	72	31772	57211	50516069
Gingival pain	13.88	11.89	18	31826	5988	50567292
Injection site pustule	13.86	11.89	4	31840	70	50573210
Intention tremor	13.82	11.89	6	31838	358	50572922
Helicobacter infection	13.81	11.89	7	31837	49695	50523585
Hyperpyrexia	13.79	11.89	13	31831	3036	50570244
Hypothyroidism	13.75	11.89	50	31794	34075	50539205
Wrong technique in product usage process	13.74	11.89	9	31835	55501	50517779
Disturbance in attention	13.69	11.89	47	31797	31139	50542141
Infertility	13.68	11.89	7	31837	606	50572674
Psoriasis	13.59	11.89	14	31830	68986	50504294
Illness	13.52	11.89	40	31804	24500	50548780
Eye pain	13.48	11.89	44	31800	28405	50544875
Myopathy	13.27	11.89	22	31822	9117	50564163
Pseudocholinesterase deficiency	13.22	11.89	4	31840	83	50573197
Limb injury	13.11	11.89	35	31809	20215	50553065
Pancreatitis chronic	13.10	11.89	11	31833	2209	50571071
Internal haemorrhage	13.07	11.89	15	31829	4402	50568878
Aspiration	13.05	11.89	22	31822	9242	50564038
Poor sucking reflex	13.03	11.89	5	31839	217	50573063
Fibromyalgia	13.00	11.89	6	31838	44972	50528308
Exposed bone in jaw	12.79	11.89	12	31832	2788	50570492
Catheter site haemorrhage	12.75	11.89	12	31832	2798	50570482
Dysphagia	12.73	11.89	88	31756	77430	50495850
Odynophagia	12.70	11.89	18	31826	6514	50566766
Onychoclasis	12.68	11.89	16	31828	5180	50568100
Hypoaesthesia	12.62	11.89	129	31715	127128	50446152
Pharyngeal hypoaesthesia	12.41	11.89	5	31839	247	50573033
Sclerodactylia	12.41	11.89	4	31840	103	50573177
Arthritis	12.26	11.89	95	31749	86626	50486654
Aphthous ulcer	12.15	11.89	23	31821	10574	50562706
Pneumonia aspiration	12.13	11.89	45	31799	30959	50542321
Salivary gland cancer stage IV	11.94	11.89	3	31841	30	50573250
Aortic embolus	11.94	11.89	3	31841	30	50573250
Mucosal haemorrhage	11.93	11.89	7	31837	793	50572487
Neck pain	11.91	11.89	11	31833	57056	50516224

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
On and off phenomenon	68.12	13.65	26	10966	1902	29561633
Regurgitation	66.23	13.65	23	10969	1284	29562251
Oropharyngeal discomfort	44.98	13.65	21	10971	2535	29561000
Vitamin B12 deficiency	42.94	13.65	22	10970	3249	29560286
Eructation	41.47	13.65	23	10969	3983	29559552
Stoma site discharge	38.37	13.65	14	10978	903	29562632
Stoma site erythema	35.41	13.65	12	10980	622	29562913
Intentional medical device removal by patient	33.81	13.65	9	10983	201	29563334
Vomiting	31.62	13.65	159	10833	212101	29351434
Device dislocation	31.21	13.65	20	10972	4507	29559028
Hyperkinesia	30.83	13.65	14	10978	1585	29561950
Oesophagitis	29.94	13.65	29	10963	11894	29551641
Dyspepsia	28.85	13.65	45	10947	30080	29533455
Oesophageal haemorrhage	28.42	13.65	12	10980	1141	29562394
Stoma site inflammation	27.38	13.65	9	10983	424	29563111
Saliva altered	26.40	13.65	7	10985	154	29563381
Drug ineffective	25.78	13.65	61	10931	363109	29200426
Akinesia	25.01	13.65	13	10979	1977	29561558
Impaired gastric emptying	24.79	13.65	15	10977	3055	29560480
Aspiration	24.14	13.65	24	10968	10156	29553379
Cataract	23.65	13.65	35	10957	22343	29541192
Dysphagia	22.00	13.65	57	10935	54869	29508666
Stoma site pain	22.00	13.65	8	10984	511	29563024
Impulse-control disorder	21.35	13.65	10	10982	1215	29562320
Toxicity to various agents	21.20	13.65	20	10972	173641	29389894
Freezing phenomenon	21.06	13.65	10	10982	1253	29562282
Electrocardiogram QT prolonged	19.35	13.65	42	10950	36095	29527440
Embedded device	19.34	13.65	6	10986	234	29563301
Lower respiratory tract infection	19.25	13.65	35	10957	26467	29537068
Dyskinesia	19.24	13.65	30	10962	20031	29543504
Inappropriate antidiuretic hormone secretion	19.24	13.65	22	10970	10910	29552625
Paralysis recurrent laryngeal nerve	18.20	13.65	4	10988	38	29563497
Pneumonia aspiration	17.77	13.65	41	10951	36696	29526839
Completed suicide	17.25	13.65	6	10986	90240	29473295
Sputum increased	17.08	13.65	10	10982	1917	29561618
Dyskinesia oesophageal	16.99	13.65	4	10988	53	29563482
Gastroenteritis	16.71	13.65	22	10970	12594	29550941
Stoma site infection	16.28	13.65	7	10985	696	29562839
Bradykinesia	16.13	13.65	12	10980	3435	29560100
Fanconi syndrome	16.06	13.65	9	10983	1589	29561946
Dermatitis atopic	15.78	13.65	10	10982	2209	29561326
Skin erosion	15.37	13.65	9	10983	1727	29561808
Shock symptom	15.08	13.65	4	10988	88	29563447
Renal tubular acidosis	15.05	13.65	9	10983	1794	29561741
Post inflammatory pigmentation change	15.02	13.65	5	10987	245	29563290
Lumbosacral plexus injury	14.86	13.65	3	10989	18	29563517
General physical health deterioration	14.52	13.65	76	10916	102781	29460754
Pyroglutamic acidosis	14.48	13.65	5	10987	274	29563261
Device related infection	14.47	13.65	23	10969	15613	29547922
Colitis ischaemic	14.31	13.65	14	10978	5809	29557726
Drug abuse	14.12	13.65	6	10986	79877	29483658

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastric pH decreased	116.86	11.68	35	40604	700	64457393
Derealisation	114.67	11.68	41	40598	1454	64456639
Completed suicide	105.12	11.68	10	40629	224404	64233689
Depersonalisation/derealisation disorder	100.03	11.68	38	40601	1602	64456491
On and off phenomenon	90.68	11.68	40	40599	2479	64455614
Premature labour	86.40	11.68	56	40583	7564	64450529
Drug ineffective	81.20	11.68	266	40373	839981	63618112
Vomiting	78.97	11.68	605	40034	550512	63907581
H1N1 influenza	78.42	11.68	35	40604	2231	64455862
Hypoaesthesia oral	78.00	11.68	62	40577	11518	64446575
Dissociation	74.82	11.68	37	40602	2974	64455119
Feeling of despair	74.23	11.68	35	40604	2533	64455560
Cogwheel rigidity	70.72	11.68	35	40604	2818	64455275
Hyperprolactinaemia	67.07	11.68	38	40601	4027	64454066
Menstrual disorder	65.27	11.68	35	40604	3330	64454763
Stoma site discharge	64.75	11.68	28	40611	1654	64456439
Stoma site erythema	62.45	11.68	25	40614	1214	64456879
Muscle disorder	57.64	11.68	37	40602	4914	64453179
Parosmia	57.32	11.68	36	40603	4604	64453489
Sensory loss	57.12	11.68	49	40590	10120	64447973
Feeling of body temperature change	56.11	11.68	36	40603	4778	64453315
Dyskinesia	56.06	11.68	94	40545	39294	64418799
Restless legs syndrome	55.52	11.68	61	40578	17055	64441038
Pituitary tumour benign	53.51	11.68	27	40612	2266	64455827
Cestode infection	51.93	11.68	15	40624	263	64457830
Pulmonary malformation	51.28	11.68	13	40626	135	64457958
Dystonia	50.68	11.68	61	40578	18804	64439289
Drooling	50.47	11.68	35	40604	5284	64452809
Mood swings	49.43	11.68	58	40581	17410	64440683
Electrocardiogram QT prolonged	48.09	11.68	134	40505	79314	64378779
Therapeutic product ineffective	48.01	11.68	22	40617	1491	64456602
Product dose omission issue	47.80	11.68	32	40607	194715	64263378
Neutropenic sepsis	45	11.68	64	40575	23208	64434885
Toxicity to various agents	44.73	11.68	102	40537	363411	64094682
Gangrene	44.59	11.68	37	40602	7301	64450792
Hallucinations, mixed	44.21	11.68	34	40605	6018	64452075
Decreased appetite	43.63	11.68	315	40324	280974	64177119
Premenstrual syndrome	42.58	11.68	15	40624	509	64457584
Arterial occlusive disease	39.72	11.68	34	40605	6999	64451094
Schizophrenia	38.31	11.68	41	40598	11127	64446966
Lip pruritus	38.24	11.68	15	40624	690	64457403
Muscle rigidity	38.22	11.68	51	40588	17422	64440671
Magnesium deficiency	37.81	11.68	14	40625	549	64457544
Mydriasis	37.09	11.68	47	40592	15265	64442828
Drug abuse	36.35	11.68	19	40620	132355	64325738
Skin discolouration	36.10	11.68	73	40566	35182	64422911
Lung cyst	35.65	11.68	10	40629	157	64457936
Akathisia	35.57	11.68	40	40599	11470	64446623
Arthropathy	35.29	11.68	16	40623	120951	64337142
Lichen sclerosus	34.75	11.68	15	40624	882	64457211
Polymenorrhoea	34.54	11.68	15	40624	895	64457198
Emotional disorder	34.25	11.68	41	40598	12566	64445527
Menstruation delayed	34.12	11.68	16	40623	1143	64456950
Paralysis	33.64	11.68	39	40600	11556	64446537
Hallucination, auditory	33.36	11.68	47	40592	16892	64441201
Exposure via breast milk	33.15	11.68	14	40625	780	64457313
Synovitis	32.37	11.68	11	40628	99079	64359014
Psychotic disorder	32.36	11.68	69	40570	34509	64423584
Mental disorder	31.03	11.68	58	40581	26387	64431706
Therapeutic product effect decreased	31.02	11.68	17	40622	115334	64342759
Constipation	30.59	11.68	248	40391	229089	64229004
Basal ganglion degeneration	30.58	11.68	11	40628	397	64457696
Aspiration	30.55	11.68	45	40594	16840	64441253
Regurgitation	30.24	11.68	18	40621	2091	64456002
Uterine enlargement	30.06	11.68	13	40626	768	64457325
Forced vital capacity decreased	30.05	11.68	16	40623	1500	64456593
Tissue infiltration	30.01	11.68	12	40627	581	64457512
Freezing phenomenon	29.76	11.68	16	40623	1530	64456563
Impaired gastric emptying	29.63	11.68	32	40607	8772	64449321
Feeling jittery	29.57	11.68	35	40604	10600	64447493
Tinnitus	29.54	11.68	66	40573	34067	64424026
Incontinence	29.13	11.68	37	40602	12044	64446049
Cardiac failure congestive	28.75	11.68	24	40615	130556	64327537
Cataract	28.62	11.68	84	40555	51178	64406915
Secondary adrenocortical insufficiency	28.48	11.68	18	40621	2327	64455766
Stoma site pain	28.38	11.68	14	40625	1119	64456974
Maternal exposure during breast feeding	28.37	11.68	17	40622	1999	64456094
Systemic lupus erythematosus	28.32	11.68	7	40632	77605	64380488
Total lung capacity decreased	28.14	11.68	16	40623	1706	64456387
Lung diffusion test decreased	27.66	11.68	14	40625	1182	64456911
Hyperchlorhydria	27.49	11.68	16	40623	1783	64456310
Nightmare	27.11	11.68	48	40591	20945	64437148
Stoma site inflammation	26.93	11.68	11	40628	563	64457530
Gingival pain	26.61	11.68	26	40613	6341	64451752
Renal failure	26.60	11.68	46	40593	181642	64276451
Thyroid stimulating immunoglobulin increased	26.39	11.68	7	40632	88	64458005
Nail dystrophy	26.36	11.68	12	40627	801	64457292
Abdominal tenderness	26.23	11.68	31	40608	9374	64448719
Folate deficiency	25.79	11.68	18	40621	2745	64455348
Oral cavity fistula	25.19	11.68	11	40628	665	64457428
Chronic sinusitis	25.01	11.68	25	40614	6267	64451826
Hepatic enzyme increased	24.96	11.68	27	40612	129916	64328177
Rhinalgia	24.86	11.68	13	40626	1175	64456918
Gastrooesophageal reflux disease	24.78	11.68	111	40528	83032	64375061
Hyperkinesia	24.74	11.68	17	40622	2529	64455564
Tremor	24.69	11.68	169	40470	148061	64310032
Neuropathy peripheral	24.56	11.68	142	40497	117383	64340710
Stoma site infection	24.39	11.68	13	40626	1222	64456871
Akinesia	24.04	11.68	18	40621	3061	64455032
Subileus	24.00	11.68	22	40617	4955	64453138
Restlessness	23.96	11.68	67	40572	39718	64418375
Impulse-control disorder	23.94	11.68	14	40625	1574	64456519
Inguinal hernia	23.72	11.68	23	40616	5558	64452535
Bronchopulmonary aspergillosis allergic	23.67	11.68	14	40625	1608	64456485
Lower respiratory tract infection	23.61	11.68	120	40519	94494	64363599
Stoma site hypergranulation	23.52	11.68	9	40630	387	64457706
Anaesthesia	23.03	11.68	9	40630	410	64457683
Hypokalaemia	22.74	11.68	143	40496	121760	64336333
Biliary sepsis	22.62	11.68	13	40626	1415	64456678
Blood sodium decreased	22.22	11.68	54	40585	29428	64428665
Mania	22.02	11.68	38	40601	16248	64441845
Sleep disorder	21.93	11.68	85	40554	59624	64398469
Intentional medical device removal by patient	21.90	11.68	8	40631	302	64457791
Serotonin syndrome	21.57	11.68	64	40575	39218	64418875
Joint swelling	21.48	11.68	67	40572	215315	64242778
Contraindicated product administered	21.16	11.68	22	40617	107807	64350286
Rash	21.14	11.68	186	40453	458363	63999730
Respiratory tract malformation	21.00	11.68	5	40634	39	64458054
Body temperature fluctuation	20.81	11.68	17	40622	3281	64454812
Cyanosis	20.48	11.68	44	40595	22111	64435982
Blepharospasm	20.47	11.68	17	40622	3358	64454735
Fanconi syndrome	20.38	11.68	15	40624	2486	64455607
Dysphagia	20.36	11.68	126	40513	106686	64351407
Vascular encephalopathy	20.32	11.68	9	40630	563	64457530
Delirium	19.59	11.68	91	40548	69103	64388990
Gastric disorder	19.41	11.68	51	40588	29146	64428947
Glomerulonephritis chronic	19.14	11.68	7	40632	265	64457828
Pneumonia aspiration	19.08	11.68	81	40558	59190	64398903
Drug hypersensitivity	19.07	11.68	81	40558	237734	64220359
Dementia	18.92	11.68	41	40598	20725	64437368
Oesophageal haemorrhage	18.84	11.68	12	40627	1572	64456521
Stoma complication	18.67	11.68	8	40631	462	64457631
Treatment failure	18.57	11.68	28	40611	116788	64341305
Pallor	18.35	11.68	60	40579	38721	64419372
Taste disorder	18.32	11.68	26	40613	9407	64448686
Adrenal suppression	18.18	11.68	11	40628	1316	64456777
Axillary pain	17.86	11.68	12	40627	1720	64456373
Hypomagnesaemia	17.84	11.68	58	40581	37318	64420775
Overdose	17.84	11.68	47	40592	159519	64298574
Speech disorder	17.82	11.68	69	40570	48372	64409721
Nail bed tenderness	17.74	11.68	7	40632	327	64457766
Myocardial infarction	17.67	11.68	50	40589	165771	64292322
Coronary artery disease	17.61	11.68	8	40631	60425	64397668
Gastritis fungal	17.51	11.68	6	40633	187	64457906
Abdominal pain	17.42	11.68	285	40354	312090	64146003
Heart rate increased	17.32	11.68	114	40525	98561	64359532
Maternal exposure during pregnancy	17.24	11.68	21	40618	95863	64362230
Cardio-respiratory arrest	17.22	11.68	22	40617	98371	64359722
Psychogenic seizure	17.20	11.68	12	40627	1829	64456264
Sputum discoloured	17.13	11.68	36	40603	17820	64440273
Lung opacity	17.13	11.68	15	40624	3184	64454909
Anti-cyclic citrullinated peptide antibody positive	17.08	11.68	5	40634	49557	64408536
Oral candidiasis	16.94	11.68	42	40597	23170	64434923
Vulvovaginal pruritus	16.94	11.68	12	40627	1874	64456219
Pyrexia	16.90	11.68	466	40173	558178	63899915
Paranoia	16.90	11.68	34	40605	16318	64441775
Vitamin B12 deficiency	16.88	11.68	19	40620	5453	64452640
Injection site erythema	16.87	11.68	12	40627	70788	64387305
Infusion site vesicles	16.64	11.68	7	40632	386	64457707
Cerebrovascular accident	16.56	11.68	39	40600	137544	64320549
Diarrhoea	16.37	11.68	582	40057	722122	63735971
Illness	16.33	11.68	40	40599	21898	64436195
Terminal ileitis	16.31	11.68	8	40631	632	64457461
Drug withdrawal syndrome	16.26	11.68	50	40589	31241	64426852
Saliva altered	16.18	11.68	7	40632	414	64457679
Monoplegia	16.18	11.68	15	40624	3428	64454665
Pyelonephritis acute	16.13	11.68	18	40621	5116	64452977
Lower respiratory tract infection viral	15.95	11.68	9	40630	946	64457147
Neuroleptic malignant syndrome	15.95	11.68	43	40596	24953	64433140
Limbic encephalitis	15.95	11.68	8	40631	663	64457430
Abdominal discomfort	15.94	11.68	60	40579	182262	64275831
Eye pain	15.94	11.68	50	40589	31575	64426518
Hand deformity	15.81	11.68	10	40629	62761	64395332
Device kink	15.73	11.68	11	40628	1682	64456411
Pericarditis	15.69	11.68	10	40629	62506	64395587
Bradykinesia	15.67	11.68	20	40619	6540	64451553
Urinary retention	15.65	11.68	67	40572	49134	64408959
Suicidal ideation	15.63	11.68	83	40556	66459	64391634
Oropharyngeal discomfort	15.57	11.68	18	40621	5317	64452776
Torsade de pointes	15.50	11.68	34	40605	17329	64440764
Discomfort	15.31	11.68	17	40622	80861	64377232
Bezoar	15.27	11.68	12	40627	2191	64455902
Anti-thyroid antibody positive	15.27	11.68	7	40632	475	64457618
Hypersensitivity	15.09	11.68	68	40571	196384	64261709
Stoma site extravasation	14.96	11.68	6	40633	293	64457800
Adverse drug reaction	14.93	11.68	5	40634	45459	64412634
Repetitive strain injury	14.91	11.68	5	40634	146	64457947
Febrile neutropenia	14.79	11.68	182	40457	187475	64270618
Infertility	14.74	11.68	7	40632	515	64457578
Oesophagitis	14.60	11.68	38	40601	21592	64436501
Limb injury	14.56	11.68	40	40599	23465	64434628
Hypochromic anaemia	14.51	11.68	12	40627	2356	64455737
Vision blurred	14.46	11.68	102	40537	90214	64367879
Dyskinesia oesophageal	14.43	11.68	4	40635	60	64458033
Shock symptom	14.38	11.68	5	40634	163	64457930
Poor sucking reflex	14.37	11.68	4	40635	61	64458032
Pulmonary function test decreased	14.35	11.68	19	40620	6442	64451651
Onychoclasis	14.26	11.68	16	40623	4576	64453517
Vulvovaginal burning sensation	14.19	11.68	9	40630	1170	64456923
Sequestrectomy	14.18	11.68	8	40631	841	64457252
Bronchiectasis	14.14	11.68	29	40610	14111	64443982
Exposed bone in jaw	14.13	11.68	14	40625	3473	64454620
Functional residual capacity decreased	13.85	11.68	4	40635	70	64458023
Psoriatic arthropathy	13.80	11.68	5	40634	43276	64414817
Aggression	13.66	11.68	6	40633	46226	64411867
Psoriasis	13.65	11.68	15	40624	71688	64386405
Faecaloma	13.55	11.68	23	40616	9705	64448388
General physical health deterioration	13.50	11.68	192	40447	204233	64253860
Injection site pustule	13.50	11.68	4	40635	77	64458016
Dysaesthesia pharynx	13.39	11.68	5	40634	201	64457892
Mucosal inflammation	13.32	11.68	76	40563	62508	64395585
Lumbosacral plexus injury	13.29	11.68	3	40636	18	64458075
Angina pectoris	13.29	11.68	60	40579	45021	64413072
Sinus bradycardia	13.24	11.68	38	40601	22855	64435238
Lung disorder	13.10	11.68	74	40565	60626	64397467
Wrong technique in product usage process	13.04	11.68	13	40626	64961	64393132
Dyspepsia	13.03	11.68	91	40548	80221	64377872
Bone marrow failure	12.98	11.68	7	40632	47945	64410148
Obstructive airways disorder	12.94	11.68	38	40601	23147	64434946
Glossodynia	12.92	11.68	13	40626	64683	64393410
Duodenal stenosis	12.91	11.68	7	40632	681	64457412
Intestinal dilatation	12.90	11.68	11	40628	2253	64455840
Injury	12.68	11.68	10	40629	55982	64402111
Unresponsive to stimuli	12.63	11.68	64	40575	50329	64407764
Carcinoid tumour	12.62	11.68	6	40633	442	64457651
Disturbance in attention	12.35	11.68	55	40584	41019	64417074
Treatment noncompliance	12.29	11.68	6	40633	43476	64414617
Thyroxine free increased	12.22	11.68	8	40631	1099	64456994
Lacrimation increased	12.15	11.68	32	40607	18314	64439779
HER2 positive breast cancer	12.13	11.68	5	40634	262	64457831
Asthma-chronic obstructive pulmonary disease overlap syndrome	12.10	11.68	8	40631	1117	64456976
Multiple organ dysfunction syndrome	12.00	11.68	29	40610	101384	64356709
Swelling	11.98	11.68	56	40583	160162	64297931
Nausea	11.94	11.68	607	40032	785193	63672900
Gastrointestinal sounds abnormal	11.94	11.68	15	40624	4828	64453265
Emotional distress	11.77	11.68	4	40635	36034	64422059
Adrenal insufficiency	11.74	11.68	36	40603	22451	64435642
Deep vein thrombosis	11.73	11.68	31	40608	105151	64352942
Hepatocellular injury	11.72	11.68	58	40581	45177	64412916
Epilepsy	11.72	11.68	47	40592	33484	64424609
Needle issue	11.71	11.68	21	40618	9251	64448842
Paralysis recurrent laryngeal nerve	11.70	11.68	4	40635	124	64457969

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Generalised tonic-clonic seizure	31.25	20.09	6	7	98	84567

Pharmacologic Action:

Source	Code	Description
ATC	A03FA03	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS PROPULSIVES Propulsives
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:50919	antiemetico

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Acute gastric ulcer with perforation	contraindication	19850005
Torsades de pointes	contraindication	31722008
Acute nephropathy	contraindication	58574008
Acute gastric ulcer with hemorrhage	contraindication	89748001
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Congenital long QT syndrome	contraindication	442917000
Pituitary Prolactinoma	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Horses	Prevention of fescue toxicosis in periparturient mares	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Equidone Gel	Dechra, Ltd.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.45	acidic
pKa2	10.04	acidic
pKa3	7.79	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.40	IUPHAR	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.99	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.79	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN				WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.79	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.59	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.96	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.78	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.16	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	6.65	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.01	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	8.46	CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	6.81	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.52	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.83	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.10	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.94	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	6.28	WOMBAT-PK
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.55	DRUG MATRIX
Calmodulin	Cytosolic other	P0DP23 P0DP24 P0DP25	CALM1_HUMAN CALM2_HUMAN CALM3_HUMAN				WOMBAT-PK
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Kd	5.06	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	5.10	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.64	CHEMBL
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.77	DRUG MATRIX
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN		IC50	4.83	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.06	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.55	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	9.28	CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	7.93	CHEMBL

External reference:

ID	Source
4025225	VUID
N0000171760	NUI
D01745	KEGG_DRUG
83898-65-1	SECONDARY_CAS_RN
203007	RXNORM
4025225	VANDF
C0013015	UMLSCUI
CHEBI:31515	CHEBI
CHEMBL219916	ChEMBL_ID
D004294	MESH_DESCRIPTOR_UI
DB01184	DRUGBANK_ID
3151	PUBCHEM_CID
965	IUPHAR_LIGAND_ID
4110	INN_ID
5587267Z69	UNII
003454	NDDF
005091	NDDF
32955006	SNOMEDCT_US
384972001	SNOMEDCT_US
387181004	SNOMEDCT_US

Pharmaceutical products:

None